Lee's Pharmaceutical Holdings Limited (HKG:0950)
Hong Kong
· Delayed Price · Currency is HKD 1.410
+0.005 (0.36%)
May 28, 2025, 4:08 PM HKT
HKG:0950 Income Statement
Financials in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,400 | 1,053 | 1,233 | 1,266 | 1,217 | Upgrade
|
| Revenue Growth (YoY) | 32.95% | -14.61% | -2.61% | 4.06% | -0.18% | Upgrade
|
| Cost of Revenue | 646.61 | 501.72 | 462.39 | 459.87 | 435.65 | Upgrade
|
| Gross Profit | 753.36 | 551.31 | 770.76 | 806.28 | 781.07 | Upgrade
|
| Selling, General & Admin | 582.59 | 492.91 | 544.88 | 663.7 | 517.67 | Upgrade
|
| Research & Development | 83.83 | 96.8 | 168.89 | 243.84 | 203.29 | Upgrade
|
| Other Operating Expenses | -60.32 | -75.72 | -70.19 | -96.41 | -90.46 | Upgrade
|
| Operating Expenses | 619.8 | 515.27 | 643.31 | 901.41 | 631.68 | Upgrade
|
| Operating Income | 133.55 | 36.04 | 127.44 | -95.13 | 149.39 | Upgrade
|
| Interest Expense | -13.82 | -11.28 | -6.62 | -4.4 | -5.39 | Upgrade
|
| Interest & Investment Income | 2.13 | 1.53 | 2.39 | 5.91 | 9.07 | Upgrade
|
| Earnings From Equity Investments | -0.84 | -0.87 | -1.1 | -3.5 | -11.41 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.61 | -0.88 | -5.63 | 3.05 | 0.21 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.37 | -0.62 | -0.98 | -1.32 | -1.09 | Upgrade
|
| EBT Excluding Unusual Items | 124.27 | 23.93 | 115.51 | -95.38 | 140.79 | Upgrade
|
| Impairment of Goodwill | - | - | - | - | -2.34 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.38 | -1.43 | -46.36 | 2,300 | -203.47 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.14 | 41.63 | 0.24 | 0.04 | 155.66 | Upgrade
|
| Asset Writedown | -25.91 | -33.31 | -2.68 | -235.09 | -4.14 | Upgrade
|
| Other Unusual Items | - | -0.04 | 1.15 | - | 47.55 | Upgrade
|
| Pretax Income | 98.11 | 30.79 | 67.86 | 1,969 | 134.04 | Upgrade
|
| Income Tax Expense | 29.5 | 10.84 | 22.03 | 9.48 | 55.5 | Upgrade
|
| Earnings From Continuing Operations | 68.61 | 19.95 | 45.84 | 1,960 | 78.53 | Upgrade
|
| Minority Interest in Earnings | 24.49 | -3.25 | 5.45 | 27.29 | 50.78 | Upgrade
|
| Net Income | 93.1 | 16.7 | 51.28 | 1,987 | 129.32 | Upgrade
|
| Net Income to Common | 93.1 | 16.7 | 51.28 | 1,987 | 129.32 | Upgrade
|
| Net Income Growth | 457.55% | -67.44% | -97.42% | 1436.68% | 3.00% | Upgrade
|
| Shares Outstanding (Basic) | 589 | 589 | 589 | 589 | 588 | Upgrade
|
| Shares Outstanding (Diluted) | 589 | 589 | 589 | 589 | 588 | Upgrade
|
| Shares Change (YoY) | - | - | -0.04% | 0.15% | -0.63% | Upgrade
|
| EPS (Basic) | 0.16 | 0.03 | 0.09 | 3.38 | 0.22 | Upgrade
|
| EPS (Diluted) | 0.16 | 0.03 | 0.09 | 3.37 | 0.22 | Upgrade
|
| EPS Growth | 457.53% | -67.44% | -97.42% | 1434.25% | 3.67% | Upgrade
|
| Free Cash Flow | 198.06 | 80.65 | 266.18 | 159.99 | 80.52 | Upgrade
|
| Free Cash Flow Per Share | 0.34 | 0.14 | 0.45 | 0.27 | 0.14 | Upgrade
|
| Dividend Per Share | 0.045 | 0.018 | 0.020 | 0.061 | 0.058 | Upgrade
|
| Dividend Growth | 150.00% | -10.00% | -67.21% | 5.17% | 3.57% | Upgrade
|
| Gross Margin | 53.81% | 52.35% | 62.50% | 63.68% | 64.20% | Upgrade
|
| Operating Margin | 9.54% | 3.42% | 10.33% | -7.51% | 12.28% | Upgrade
|
| Profit Margin | 6.65% | 1.59% | 4.16% | 156.94% | 10.63% | Upgrade
|
| Free Cash Flow Margin | 14.15% | 7.66% | 21.58% | 12.64% | 6.62% | Upgrade
|
| EBITDA | 220.26 | 130.62 | 237.9 | 16.83 | 260.95 | Upgrade
|
| EBITDA Margin | 15.73% | 12.40% | 19.29% | 1.33% | 21.45% | Upgrade
|
| D&A For EBITDA | 86.71 | 94.58 | 110.46 | 111.96 | 111.56 | Upgrade
|
| EBIT | 133.55 | 36.04 | 127.44 | -95.13 | 149.39 | Upgrade
|
| EBIT Margin | 9.54% | 3.42% | 10.33% | -7.51% | 12.28% | Upgrade
|
| Effective Tax Rate | 30.07% | 35.20% | 32.46% | 0.48% | 41.41% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.